SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to a significant investment from Nvidia, viewed by the community as a major vote of confidence and a potential turning point for the company's competitive standing. The news has sparked discussions about future partnerships, manufacturing capabilities, and the broader implications for the semiconductor industry. Despite some analyst downgrades based on valuation concerns, the community remains optimistic about Intel's long-term prospects and potential deals with other tech giants.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to its rebranding as Solmate and a $300M investment to focus on Solana's digital asset space, sparking excitement and volatility. The community is discussing the involvement of ARK Invest and potential for high gains, while also debating dilution risks and comparing it to other crypto-related runners. Speculation around short squeezes and future price targets is rampant amid the stock's wild swings.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to significant price volatility, triggering multiple trading halts and prompting discussions about potential short squeezes. Community members are actively debating entry points and sharing profit-taking strategies, while also highlighting the company's merger agreement and low float as potential catalysts for further movement. The stock's performance is also being compared to other SPACs and companies in the sector.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar is trending due to recent earnings reports, which revealed a drop in profit and missed forecasts, while Q3 guidance lowered delivery estimates, sparking mixed reactions from investors. Despite disappointing results, Berkshire Hathaway's major stake in Lennar may signal confidence in the homebuilder and real estate sector. Community discussions revolve around the impact of interest rates and affordability on the housing market and the potential effect of these factors on Lennar's performance.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest the completed acquisition of Melinta Therapeutics, a move aimed at diversifying their portfolio, but is met with mixed reactions from the community. While the deal is expected to boost earnings per share by 2026 and expand into hospital-focused markets, some express concerns about short-term dilution and uncertainty regarding DefenCath's long-term viability. Community discussions revolve around the revised financial guidance, potential synergies, and the path forward for the company's growth.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to discussions surrounding the potential for European Medicines Agency (EMA) approval of Blarcamesine, with community members closely monitoring the EMA's agenda and speculating on the timing of a decision. The focus centers on whether further data will be requested by regulators, potentially delaying the approval timeline. Despite positive data, some traders express concerns about the stock's price action and await significant movement upon approval.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following the release of its earnings report, which initially sparked an after-hours surge but was followed by a pullback due to cautious forward guidance amid concerns about trade and tariffs. The community is actively debating whether the dip represents a buying opportunity, given the company's cost-cutting initiatives and strong Q4 performance, or a sign of deeper challenges in the global shipping environment. Some traders anticipate a potential short squeeze, while others are wary of the uncertainty surrounding future earnings.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN is trending amid discussions around its pipeline, particularly in obesity with MariTide, as well as analyst ratings and Q4 earnings. Community members are weighing Amgen's potential in the competitive obesity market and comparing it to other biotech companies. The focus is on upcoming data readouts and strategic moves in the biopharmaceutical space.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users promote its connection to cannabis culture and community, emphasizing its positive vibes and long-term vision. The community highlights its unique position as a culture coin, drawing parallels to Bitcoin but with a focus on the cannabis industry and lifestyle. Discussions also revolve around its presence on the Solana blockchain.

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Kala Pharmaceuticals Inc

Kala Pharmaceuticals is trending as traders discuss upcoming data, potential for a squeeze given its low float, and comparisons to previous runners like $KOD. Community members are pointing to institutional investment from Baker Bros, Cohen, and Edelman, while also acknowledging risks associated with potential data disappointments. Some are speculating on buyout potential and significant price appreciation based on positive results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FUTU or ZETA: Which Is the Better Value Stock Right Now?

FUTU vs. ZETA: Which Stock Is the Better Value Option?

Zeta Global Holdings Corp. (ZETA) is receiving praise from Wall Street after delivering a strong second-quarter (Q2) performance that beat expectations and sparked optimism for future growth.&nbsp;Two major research firms have boosted their price targets, citing confidence in the company’s data capabilities and strategic direction.Canaccord Genuity analyst David Hynes revised his outlook on Zeta, lifting the firm’s target price to $28 from $26 while maintaining a ‘Buy’ recommendation, as per TheFly.&nbsp;<a href="https://stocktwits.com/symbol/ZETA">Zeta Global stock</a> traded over 25% on Wednesday afternoon. On Stocktwits, retail sentiment around the stock shifted to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume jumped to ‘extremely high’ from ‘normal’ levels in 24 hours.<figure class="image"><img style="aspect-ratio:958/116;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_140306_png_9e04c01236.webp" alt="ZETA’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="958" height="116"><figcaption>ZETA’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 710% surge in user message count over 24 hours. A Stocktwits user commended the earnings.<stembedurl>https://stocktwits.com/WolfMoney/message/623980005</stembedurl>Another user said the stock is ‘undoubtedly impressive’.<stembedurl>https://stocktwits.com/Zaksab/message/623978335</stembedurl>Hynes highlighted the company’s across-the-board strength in Q2 and pointed to several growth drivers, including the expanding use of its OneZeta platform among targeted clients and emerging opportunities tied to AI and agency partnerships.&nbsp;BofA Securities also raised its forecast, increasing its price target on the stock to $24 from $20, while reiterating a ‘Buy’ rating. According to the research firm, Zeta’s Q2 revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) outperformed both its internal projections and market consensus.&nbsp;The brokerage credited Zeta’s unique combination of data assets and execution strength as key differentiators in a competitive landscape and added that stronger results are expected in upcoming quarters.Zeta Global stock has gained over 11% year-to-date and has shed over 12% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wall-street-split-on-super-micro-as-q4-misses-expectations/chrS3PCRd5V">Wall Street Split On Super Micro As Q4 Misses Expectations But AI Hopes Persist: Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Zeta Global Holdings Corp. 

Zeta Global Wins Analyst Confidence With Strong Q2: Retail Chatter Surge Over 700% In 24 Hours

Canaccord Genuity and BofA have boosted their price targets, citing confidence in Zeta Global’s data capabilities and strategic direction.

Equity

Zeta Global Holdings (ZETA) Matches Q2 Earnings Estimates

Zeta (ZETA) delivered earnings and revenue surprises of 0.00% and +4.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ZETA Stock Before Q2 Earnings Release: To Buy or Not to Buy?

Zeta Holdings' second-quarter 2025 earnings loom amid weak beat odds, ad spend risks and a 34.8% stock drop. Should investors stay away?

MediaAlpha, Inc. (MAX) Reports Next Week: Wall Street Expects Earnings Growth

MediaAlpha (MAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zeta Global Holdings (ZETA) Earnings Expected to Grow: Should You Buy?

Zeta (ZETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zeta (ZETA) Moves 6.2% Higher: Will This Strength Last?

Zeta (ZETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zeta Announces Record Financial Results and Zeta 2028 Targets

Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced financial results for the fourth quarter and full year ended December 31, 2024. At Zeta, weve consistently skated to where the puck...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zeta Global Holdings Corp. (NYSE: ZETA)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zeta Global Holdings Corp. (NYSE: ZETA) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Taylor Swift's Football Effect Drops 20% from 2024 While Ad Anticipation Surges, Zeta Global Data Shows

Zeta Global (NYSE: ZETA), the AI-powered marketing cloud, released findings of real-time consumer insights ahead of this Sundays big game. Analyzing behavioral signals from over 245 million US...

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

ZETA
Zeta Global Holdings Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ZETA News

ZETA Zeta Global Holdings Corp